Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CAN-2409 + Prodrug in Borderline Resectable Pancreatic Cancer
NCT02446093Phase 2Active, not recruiting
- Sponsor
- Candel Therapeutics
- Start
- Oct 2015
- Primary completion
- Dec 2025
- Modality
- Gene Editing, Gene Silencing, Oncolytic Viruses
- Countries
- 2
01
Overview
A Phase 2 trial of aglatimagene besadenovec in pancreatic adenocarcinoma (PDAC), sponsored by Candel Therapeutics. Started Oct 2015; status: active, not recruiting.
02
Drugs
aglatimagene besadenovec
03
Conditions
pancreatic adenocarcinoma (PDAC)
Beyond the preview
Go deeper on NCT02446093.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02446093.